Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$15.83 - $23.35 $346,677 - $511,365
21,900 New
21,900 $449,000
Q2 2023

Aug 14, 2023

SELL
$23.37 - $32.96 $2.14 Million - $3.02 Million
-91,500 Reduced 77.61%
26,400 $779,000
Q1 2023

May 15, 2023

SELL
$21.91 - $32.67 $742,749 - $1.11 Million
-33,900 Reduced 22.33%
117,900 $2.72 Million
Q4 2022

Feb 14, 2023

SELL
$26.28 - $33.92 $840,960 - $1.09 Million
-32,000 Reduced 17.41%
151,800 $4.22 Million
Q3 2022

Nov 14, 2022

BUY
$25.97 - $38.53 $605,101 - $897,749
23,300 Added 14.52%
183,800 $5.64 Million
Q2 2022

Aug 15, 2022

SELL
$20.88 - $35.19 $244,296 - $411,723
-11,700 Reduced 6.79%
160,500 $4.72 Million
Q1 2022

May 16, 2022

SELL
$29.0 - $47.27 $2.82 Million - $4.6 Million
-97,400 Reduced 36.13%
172,200 $5.54 Million
Q4 2021

Feb 14, 2022

SELL
$42.59 - $55.02 $6.45 Million - $8.34 Million
-151,500 Reduced 35.98%
269,600 $12 Million
Q3 2021

Nov 15, 2021

SELL
$48.48 - $78.23 $2.08 Million - $3.36 Million
-43,000 Reduced 9.27%
421,100 $21.2 Million
Q2 2021

Aug 16, 2021

BUY
$50.3 - $78.44 $643,840 - $1 Million
12,800 Added 2.84%
464,100 $36.4 Million
Q1 2021

May 17, 2021

BUY
$53.8 - $81.53 $10.2 Million - $15.5 Million
190,200 Added 72.85%
451,300 $25.8 Million
Q4 2020

Feb 16, 2021

BUY
$36.89 - $93.56 $7.4 Million - $18.8 Million
200,700 Added 332.28%
261,100 $21.9 Million
Q3 2020

Nov 16, 2020

BUY
$23.13 - $38.84 $1.11 Million - $1.87 Million
48,200 Added 395.08%
60,400 $2.16 Million
Q2 2020

Aug 14, 2020

BUY
$16.01 - $28.82 $195,322 - $351,604
12,200 New
12,200 $295,000

Others Institutions Holding DNLI

About Denali Therapeutics Inc.


  • Ticker DNLI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 134,174,000
  • Market Cap $3.9B
  • Description
  • Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...
More about DNLI
Track David A. Siegel's Portfolio

Track David A. Siegel Portfolio

Follow David A. Siegel (Two Sigma Advisers, LP) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.